摘要
目的 探讨超声造影参数联合血清成纤维细胞生长因子-23(fibroblast growth factor-23,FGF23)和成纤维细胞生长因子受体1(fibroblast growth factor receptor 1,FGFR1)在诊断乳腺癌的临床应用价值。方法 选择2020年8月~2022年6月在新疆维吾尔自治区人民医院就诊的87例乳腺癌患者作为观察对象(恶性组),选取同期90例乳腺良性病变患者作为良性组,分析两组观察对象超声造影参数,酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)检测血清FGF23和FGFR1表达水平,Pearson法分析乳腺癌患者血清FGF23和FGFR1水平与超声造影参数的相关性,ROC曲线分析超声造影参数、血清FGF23和FGFR1对乳腺癌的诊断价值。结果 与良性组比较,恶性组的超声造影峰值强度(peak intensity,PI)(15.36±3.47 dB vs 12.54±2.83 dB)、曲线下面积(area under curve,AUC)(382.69±90.51 dB/s vs 262.95±75.34 dB/s)及血清FGF23(119.28±26.41 pg/ml vs 86.41±20.35 pg/ml),FGFR1(11.36±3.42 ng/mL vs 7.24±2.26 ng/mL)水平升高,达峰时间(time to peak,TTP)(18.46±4.31 s vs 24.23±5.25 s)降低,差异均有统计学意义(t=5.934~9.579,均P=0.000)。相关性分析显示,乳腺癌患者血清FGF23水平与PI,AUC呈正相关(r=0.493,0.561,均P=0.000),与TTP呈负相关(r=-0.572,P=0.000);血清FGFR1水平与PI,AUC呈正相关(r=0.603,0.491,均P=0.000),与TTP呈负相关(r=-0.545,P=0.000)。超声造影参数联合血清FGF23和FGFR1诊断乳腺癌的曲线下面积为0.971,联合诊断效能明显高于单独诊断,差异均有统计学意义(Z=6.478,5.558,4.839,4.780,4.943,均P <0.05)。结论 超声造影参数联合血清FGF23和FGFR1对乳腺癌具有较高诊断价值,可为乳腺癌的临床诊治提供参考。
Objective To investigate the clinical value of contrast-enhanced ultrasound parameters combined with serumfibroblast growth factor-23(FGF23)andfibroblast growth factor receptor 1(FGFR1)in the diagnosis of breast cancer.Methods From August 2020 to June 2022,87 breast cancer patients who were treated in Xinjiang Uygur Autonomous Region People’s Hospital were regarded as observation objects(malignant group),90 patients with benign breast lesions during the same period were regarded as the benign group and the contrast-enhanced ultrasound parameters of observation objects in the two groups were analyzed.Enzyme-linked immunosorbent assay(ELISA)was used to detect the expression levels of serum FGF23 and FGFR1,Pearson method was applied to analyze the correlation between serum FGF23 and FGFR1 levels and contrast-enhanced ultrasound parameters in breast cancer patients.ROC curves were applied to analyze the diagnostic value of contrast-enhanced ultrasound parameters,serum FGF23,and FGFR1 for breast cancer.Results Compared with the benign group,the values of contrast-enhanced ultrasound peak intensity(PI)(15.36±3.47 dB vs 12.54±2.83 dB),area under curve(AUC)(382.69±90.51 dB/s vs 262.95±75.34 dB/s),serum FGF23(119.28±26.41 pg/ml vs 86.41±20.35 pg/ml)and FGFR1(11.36±3.42 ng/ml vs 7.24±2.26 ng/ml)levels in the malignant group were increased,while time to peak(TTP)(18.46±4.31s vs 24.23±5.25s)was decreased,with statistical significance(t=5.934~9.579,all P=0.000).Correlation analysis showed that serum FGF23 level in breast cancer patients were positively correlated with PI and AUC(r=0.493,0.561,all P=0.000),and negatively correlated with TTP(r=-0.572,P=0.000).Serum FGFR1 level was positively correlated with PI and AUC(r=0.603,0.491,all P=0.000),and negatively correlated with TTP(r=-0.545,P=0.000).The AUC of contrast-enhanced ultrasound parameters combined with serum FGF23 and FGFR1 in the diagnosis of breast cancer was 0.971,and the combined diagnostic efficiency was obviously higher than that of single diagnosis(Z=6.478,5.558,4.839,4.780,4.943,all P<0.05).Conclusion The contrast-enhanced ultrasound parameters combined with serum FGF23 and FGFR1 have high diagnostic value for breast cancer,and can provide reference for the clinical diagnosis and treatment of breast cancer.
作者
荣鹿
周敏
于鲁欣
吕娟
万静
RONG Lu;ZHOU Min;YU Luxin;LÜJuan;WAN Jing(Department of Ultrasound,Xinjiang Uygur Autonomous Region People’s Hospital,Urumqi 830002,China)
出处
《现代检验医学杂志》
CAS
2023年第5期185-189,共5页
Journal of Modern Laboratory Medicine
